Incremental economic analysis of NMS versus normal practice at 26-week follow-up
| Mean cost (2.5%, 97.5% percentiles)/£ | Mean QALY (2.5%, 97.5% percentiles) | Incremental difference (2.5%, 97.5% percentiles) | ICER: £/QALY (2.5%, 97.5% percentiles) | |||
| NMS* | Normal practice | NMS | Normal practice | Cost/£ | QALY | |
| 20 482.7 (9438.9, 53 822.0) | 20 596.5 (9435.5, 54 125.5) | 13.45 (12.55, 14.35) | 13.41 (12.50, 14.31) | −113.9 (−1159.4, 683.7) | 0.04 (−0.01, 0.13) | −2847.5 (−38 739.5, 34 024.2) |
*Incorporating cost of intervention equal to £24.6.
ICER, incremental cost-effectiveness ratio; NMS, New Medicine Service; QALY, quality-adjusted life-year.